Literature DB >> 20844565

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

J R Brown, J Abramson, E Hochberg, E Mikler, V Dalton, L Werner, H Reynolds, C Thompson, S M McDonough, Y Kuang, J Ritz, D Neuberg, A S Freedman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20844565      PMCID： PMC3722583          DOI： 10.1038/leu.2010.199

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

1.  Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.

Authors:  Laure A Moutouh-de Parseval; Lilia Weiss; Robert J DeLap; Robert D Knight; Jerome B Zeldis
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

2.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

3.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

4.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

5.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

6.  Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

Authors:  Georg Aue; Ndegwa Njuguna; Xin Tian; Susan Soto; Thomas Hughes; Berengere Vire; Keyvan Keyvanfar; Federica Gibellini; Janet Valdez; Carol Boss; Leigh Samsel; J Philip McCoy; Wyndham H Wilson; Stefania Pittaluga; Adrian Wiestner
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941
  6 in total
  19 in total

Review 1.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

2.  Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.

Authors:  Chisako Urata; Mariko Yoshimura; Hidekazu Itamura; Takashi Hisatomi; Yasushi Kubota; Noriyasu Fukushima; Eisaburo Sueoka; Shinya Kimura
Journal:  Int J Hematol       Date:  2011-08-03       Impact factor: 2.490

3.  Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia.

Authors:  Candida Vitale; Alessandra Ferrajoli
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

4.  Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Authors:  Jaime L Shahan; Lori D Panu; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2012-11-28       Impact factor: 2.490

Review 5.  Optimizing frontline therapy of CLL based on clinical and biological factors.

Authors:  Kirsten Fischer; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.

Authors:  Bang-Ning Lee; Hui Gao; Evan N Cohen; Xavier Badoux; William G Wierda; Zeev Estrov; Stefan H Faderl; Michael J Keating; Alessandra Ferrajoli; James M Reuben
Journal:  Cancer       Date:  2011-02-24       Impact factor: 6.860

Review 7.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 8.  Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Authors:  Christine I Chen
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 9.  Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.

Authors:  Sanford Kempin
Journal:  Curr Treat Options Oncol       Date:  2013-06

10.  Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Authors:  Jessie-F Fecteau; Laura G Corral; Emanuela M Ghia; Svetlana Gaidarova; Diahnn Futalan; Ila Sri Bharati; Brian Cathers; Maria Schwaederlé; Bing Cui; Antonia Lopez-Girona; Davorka Messmer; Thomas J Kipps
Journal:  Blood       Date:  2014-07-02       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.